Abbisko Cayman Limited 2025 Annual Report – Key Highlights for Investors

1. Financial Performance Overview

• Revenue Surge: The company reported a remarkable increase in revenue to RMB 612.1 million in 2025 from RMB 504.0 million in 2024. The surge is primarily attributed to licensing revenue from Merck.
• Profitability Turnaround: Abbisko Cayman Limited posted a net profit of RMB 55.2 million in 2025, up from RMB 28.3 million in 2024. This marks a significant improvement after years of operating losses (2023: RMB -431.6 million; 2022: RMB -495.6 million).
• Adjusted (Non-IFRS) Profit: Adjusted profit (excluding share-based payment expenses) stood at RMB 87.9 million in 2025, up from RMB 49.0 million in the previous year, highlighting improved core operational profitability.
• Research & Development (R&D) Investments: Total R&D expenses continued to rise, reaching RMB 508.4 million (2024: RMB 451.4 million), reflecting the company’s ongoing commitment to innovation. Adjusted R&D expenses (excl. share-based payments) were RMB 487.2 million.
• Healthy Cash Position: The company maintained strong liquidity with cash and bank balances of RMB 2.0 billion as of year-end, providing a solid foundation for future growth and R&D activities.
• Debt Profile: Interest-bearing bank borrowings increased to RMB 291.7 million (2024: Nil), all at fixed interest rates. The company’s gearing ratio jumped to 18% (2024: 7%), a factor investors should closely monitor.
• Equity and Assets: Total equity was reported at RMB 1.92 billion, and total assets at RMB 2.35 billion.

2. Operational and Strategic Highlights

• Product Pipeline: Abbisko has a robust pipeline of 21 program candidates, with a primary focus on oncology. Pimicotinib has received approval from the China NMPA, and several other candidates are in clinical stages. The company is also expanding into non-oncology areas and modalities.
• Revenue Concentration Risk: All 2025 revenue was generated from Merck’s licensing agreement. This concentration risk is important for shareholders, as changes to this partnership could significantly impact financial results.
• Share Repurchase Program: In March 2025, the board approved up to HKD 200 million for on-market share repurchases. By year-end, 10,229,000 shares had been repurchased for HKD 84.7 million, with 7,744,000 shares held as treasury shares. This action signals management’s confidence in the company’s intrinsic value and may support the share price.
• No Final Dividend: The board does not recommend a final dividend for 2025, continuing the company’s practice of reinvesting profits for growth. There were no dividends paid or declared in 2025 or 2024.
• Use of Proceeds Update: As of March 2025, the board resolved to change the use of HKD 699.73 million in unutilised IPO proceeds. Details are in the March 3, 2025 company announcement. Investors should review these changes for strategic implications.

3. Shareholding and Corporate Governance

• Key Shareholders: The largest shareholders include Trident Trust Company (HK) Limited (11.79%), Dr. Xu Yao-Chang (12.02%), Morgan Stanley (7.72%), and institutional investors such as Qiming Venture Partners VI, L.P. and Allianz SE. No new significant shareholding changes were reported.
• Director Movements: Dr. Ji Jing and Ms. Chui Hoi Yam were appointed as executive and independent non-executive directors, respectively, in early 2025.
• Corporate Governance: The company emphasizes high governance standards, strong risk management, and internal control systems. The Audit Committee, comprised solely of independent directors, oversees financial reporting and risk management.
• Share Incentive Plans: The company operates multiple equity-settled share schemes (including Post-IPO RSU and Option Schemes) to incentivize employees and directors. Share-based payment expenses were RMB 32.6 million in 2025.

4. Other Important Disclosures

• Foreign Exchange Risk: Abbisko holds assets in multiple currencies and does not currently hedge foreign exchange risk. A 5% movement in RMB against USD could impact earnings by nearly RMB 97 million.
• No Significant Post-Year Events: There were no material events after December 31, 2025 that would affect the company’s financial position or share value.
• Major Customer and Supplier Risks: Merck accounted for 100% of revenue in 2025. The largest supplier contributed 12.5% of purchases, with the top five suppliers accounting for 29.8%.
• ESG and Sustainability: The company is committed to environmental, social, and governance (ESG) best practices, with details available in the forthcoming ESG Report.

5. Potential Price-Sensitive and Shareholder-Important Issues

• Profitability Inflection Point: The shift from loss to profit, driven by Merck licensing revenue, could be a major share price catalyst. However, the high dependence on a single customer increases risk.
• Increased Debt and Gearing: The first-time introduction of RMB 291.7 million in bank borrowings and the significant jump in gearing ratio may concern risk-averse investors.
• Share Buybacks: The ongoing share repurchase program may provide downside support for the share price and reflects management’s view of undervaluation.
• R&D Commitment: Continued heavy investment in R&D suggests confidence in future pipeline value but could impact future profitability if licensing revenues are not sustained.
• Dividend Policy: The absence of dividends means the company remains focused on growth, which may not appeal to income-focused investors.
• Change in Use of IPO Proceeds: Changes in the use of IPO proceeds may affect strategic direction and should be closely monitored for any deviation from previously stated objectives.

Conclusion

The 2025 annual report signals a turning point for Abbisko Cayman Limited, with the company achieving profitability and executing a significant share repurchase program. However, the reliance on Merck for all revenue, rising R&D costs, and increased gearing ratio present both opportunities and risks for shareholders. Investors should pay close attention to the sustainability of licensing revenues, the execution of the pipeline, and any further changes in capital structure or strategic direction.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should review the full annual report and consult their financial advisors before making investment decisions. The information is based on company disclosures as of December 31, 2025, and subsequent public filings. Market conditions and company circumstances may change.

View ABBISKO-B Historical chart here